Two-Year-Old Candid Looks To Move Autoimmune TCEs Into Phase II Development

 
• By Alaric DeArment
  
Bispecific AB
Candid is advancing T-cell engagers in clinical development for autoimmune diseases. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D